OncoMatch

OncoMatch/Clinical Trials/NCT06353061

Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer

Is NCT06353061 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Metformin and Chemotherapy for cervical cancer.

Phase 2RecruitingPeking Union Medical College HospitalNCT06353061Data as of May 2026

Treatment: Metformin · ChemotherapyThis is a prospective, single-center, phase II, randomized, window-of-opportunity trial initiated by researchers. The research hypothesis is that metformin can improve the level of hypoxia in locally advanced cervical cancer and further improve progression-free survival. The study aims to compare the improvement of tumor hypoxia with synchronous chemoradiotherapy with or without metformin, using CA-IX PET/CT and radiation positioning spectral CT to evaluate tumor hypoxia, screening hypoxic patients for inclusion in the study, and comparing the effects of synchronous chemoradiotherapy with or without metformin on the degree of hypoxia and progression-free survival in the two groups of patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Disease stage

Required: Stage IIA, IIB, IIIA, IIIB, IVA (FIGO)

FIGO stage IB2-IVA

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: pelvic radiotherapy

Lab requirements

Blood counts

Hemoglobin ≥90g/L; no severe hematopoietic dysfunction

Kidney function

no significant renal dysfunction; eGFR ≥45 ml‧min-1‧1.73 m-2

Liver function

no significant hepatic dysfunction; serum transaminases ≤3x ULN; no liver failure or alcohol poisoning

Cardiac function

no significant cardiac dysfunction

Hemoglobin ≥90g/L (blood transfusions allowed); no severe hematopoietic dysfunction, and no significant cardiac, pulmonary, hepatic, renal dysfunction, or immune deficiency; Renal insufficiency with eGFR <45 ml‧min-1‧1.73 m-2, and acute conditions that may lead to renal impairment such as dehydration, severe infectious diseases, shock, etc.; Serum transaminases exceeding 3 times the upper limit of normal, liver failure, alcohol poisoning.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify